16.9.2024 10:30:08 CEST | Demant A/S |
Investor Nyheder
Investor news
16. september 2024
Ny President for Diagnostics og medlem af Demant Management
Pr. 1. november 2024 tiltræder Anne-Karen Hunt stillingen som President for Demants Diagnostics-forretningsområde. René Schneider, der sideløbende med sin rolle som CFO i Demant har været midlertidig President for forretningsområdet siden april 2023, vil hjælpe med at sikre en god overgang, når Anne-Karen Hunt tiltræder.
Anne-Karen Hunt har de seneste 20 år arbejdet for en række internationale medtech-virksomheder, senest I GE HealthCare som General Manager & President for Ultrasound International-forretningen med ansvar for EMEA-, APAC- og LATAM-regionerne.
Ud over ansvaret for Demants Diagnostics-forretningsområde træder Anne-Karen Hunt også ind i Demant Management og tager dermed del i arbejdet med at drive Demants strategi fremadrettet.
“Jeg ser frem til at byde Anne-Karen Hunt velkommen som ny President for Diagnostics og som medlem af Demant Management. Anne-Karen Hunt er en stærk profil og en strategisk tænker, som med succes har ledet store internationale organisationer, hvor hun har opnået veldokumenterede resultater inden for forretningsudvikling og performance. Hun har en samarbejdsorienteret tilgang til ledelse og fokuserer på at skabe tryghed i teams med et højt performance-niveau.
Hun er den rette profil til at lede Diagnostics-forretningsområdet i fremtiden, og jeg er sikker på, at hun vil skabe store resultater i samarbejde med de mange talentfulde mennesker i Diagnostics og også på tværs af Demant,” siger Søren Nielsen, koncernchef & adm. direktør i Demant.
Anne-Karen Hunt er tysk af nationalitet. Hendes uddannelsesmæssige baggrund er inden for marketing og økonomi, og hun har en MBA fra universitetet i Düsseldorf.
”Jeg glæder mig til at blive en del af Demant. Kombinationen af en virksomhed med et ægte engagement i høresundhed, et stærkt formål om at lette livet for mennesker med høretab og en lang historik med lønsom vækst er meget interessant for mig. I løbet af min karriere har jeg altid haft fokus på at forstå kunders behov som fundamentet for udvikling af forretningsstrategi, og jeg ser frem til at lære Diagnostics-forretningen bedre at kende og bidrage til dens fortsatte udvikling og succes,” siger Anne-Karen Hunt.
Curriculum vitae – Anne-Karen Hunt
2023 – nu: GE HealthCare
General Manager and President – Ultrasound International (EMEA, APAC, LATAM)
General Manager and President – Imaging (EMEA)
2017-2023: Abbott
Divisional VP Commercial – Abbott Cardiac Rhythm Management (EMEA)
Divisional VP Commercial – Abbott Heart Failure (AMERICAS)
International Head & General Manager – Neuromodulation (EMEA & APAC)
2002-2017: Forskellige roller hos Terumo Interventional Systems og Johnson & Johnson
Yderligere information:
Søren Nielsen, koncernchef & adm. direktør
Telefon +45 3917 7300
www.demant.com
Øvrige kontaktpersoner:
René Schneider, CFO
Peter Pudselykke, Head of Investor Relations
Henrik Axel Lynge Buchter, Manager of External Communications
Om Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Vedhæftninger
Investor news – Ny President for Diagnostics.pdf
16.9.2024 10:30:08 CEST | Demant A/S |
Investor News
Investor news
16 September 2024
New President of Diagnostics and member of Demant Management
Effective 1 November 2024, Anne-Karen Hunt will join Demant and take up the position as President of Demant’s Diagnostics business area. René Schneider, who concurrently with his role as CFO of Demant, has held the position as interim President since April 2023, will help ensure a proper transition when Anne-Karen Hunt joins the company.
Anne-Karen Hunt has spent the last 20 years of her career in various international medical technology companies, most recently in GE HealthCare where she held the position as General Manager and President of the Ultrasound International business of the EMEA, APAC and LATAM regions.
Besides taking on the responsibility for the Diagnostics business area, Anne-Karen Hunt will join Demant Management and thus take part in driving Demant’s strategy forward.
“I am looking forward to welcoming Anne-Karen Hunt as new President of Diagnostics and member of the Demant Management. Anne-Karen Hunt is a strong profile and a strategic thinker, who has successfully led large, international organisations with a proven track record of business development and performance. She has a collaborative leadership mindset and focuses on creating trust in high-performing teams.
She is the right profile for leading our Diagnostics business area into the future, and I am sure she will do great things in collaboration with the many talented people in our Diagnostics business and across Demant,” says Søren Nielsen, President and CEO in Demant.
Anne-Karen Hunt is of German nationality. Her educational background is in marketing and economics, and she holds an MBA from the University of Düsseldorf.
“I am excited to join Demant. The combination of a company truly committed to hearing healthcare, a strong purpose of making life-changing differences and a long track record of profitable growth is very interesting to me. During my career, I have always been focused on understanding the customer needs as the foundation for building business strategy, and I look forward to getting to know the Diagnostics business further and contributing to its ongoing development and success,” says Anne-Karen Hunt.
Curriculum vitae – Anne-Karen Hunt
2023 – now: GE HealthCare
General Manager and President – Ultrasound International (EMEA, APAC, LATAM)
General Manager and President – Imaging (EMEA)
2017-2023: Abbott
Divisional VP Commercial – Abbott Cardiac Rhythm Management (EMEA)
Divisional VP Commercial – Abbott Heart Failure (AMERICAS)
International Head & General Manager – Neuromodulation (EMEA & APAC)
2002-2017: Various positions with Terumo Interventional Systems and Johnson & Johnson
Further information:
Søren Nielsen, President & CEO
Phone +45 3917 7300
www.demant.com
Other contacts:
René Schneider, CFO
Peter Pudselykke, Head of Investor Relations
Henrik Axel Lynge Buchter, Manager of External Communications
About Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Attachments
Investor news – New President Diagnostics.pdf
